[go: up one dir, main page]

WO2006058243A3 - Leishmania antigens and related compositions and uses - Google Patents

Leishmania antigens and related compositions and uses Download PDF

Info

Publication number
WO2006058243A3
WO2006058243A3 PCT/US2005/042795 US2005042795W WO2006058243A3 WO 2006058243 A3 WO2006058243 A3 WO 2006058243A3 US 2005042795 W US2005042795 W US 2005042795W WO 2006058243 A3 WO2006058243 A3 WO 2006058243A3
Authority
WO
WIPO (PCT)
Prior art keywords
related compositions
leishmania antigens
leishmania
antigens
eliciting
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2005/042795
Other languages
French (fr)
Other versions
WO2006058243A2 (en
Inventor
Diane Mcmahon-Pratt
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yale University
Original Assignee
Yale University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yale University filed Critical Yale University
Publication of WO2006058243A2 publication Critical patent/WO2006058243A2/en
Publication of WO2006058243A3 publication Critical patent/WO2006058243A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/008—Leishmania antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588—Adjuvants of undefined constitution
    • A61K2039/55594—Adjuvants of undefined constitution from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/023—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a poxvirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The disclosure provides methods and formulations for eliciting an immune response to a Leishmania protein in a mammal, particularly a human or a canine.
PCT/US2005/042795 2004-11-24 2005-11-23 Leishmania antigens and related compositions and uses Ceased WO2006058243A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63098604P 2004-11-24 2004-11-24
US60/630,986 2004-11-24

Publications (2)

Publication Number Publication Date
WO2006058243A2 WO2006058243A2 (en) 2006-06-01
WO2006058243A3 true WO2006058243A3 (en) 2007-02-22

Family

ID=36498567

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/042795 Ceased WO2006058243A2 (en) 2004-11-24 2005-11-23 Leishmania antigens and related compositions and uses

Country Status (1)

Country Link
WO (1) WO2006058243A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2932802B1 (en) * 2008-06-19 2010-08-20 Oridan Inc CYCLIC NON-NATIVE SYNTHESIS PEPTIDE AND PEPTIDE COMPLEX COMPRISING SAID CYCLIC PEPTIDE FOR INDUCING AND CHARACTERIZING THE PREVENTION OR TREATMENT OF DISEASES IN MAMMALS
PL3158054T3 (en) 2014-06-17 2025-07-21 Crown Laboratories, Inc. Genetically modified bacteria and methods for genetic modification of bacteria
US11504404B2 (en) 2016-02-24 2022-11-22 Crown Laboratories, Inc. Skin probiotic formulation
US12102710B2 (en) 2020-06-23 2024-10-01 Crown Laboratories, Inc. Probiotic skin formulations

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0703295A1 (en) * 1994-09-26 1996-03-27 Institut Pasteur Vaccine composition comprising recombinant BCG expressing gp 63 fusion protein
WO2000039298A1 (en) * 1998-12-23 2000-07-06 C.B.F. Leti S.A. Chimeric gene encoding the antigenic determinants of four proteins of l. infantum
EP1018548A1 (en) * 1997-09-22 2000-07-12 Kirin Beer Kabushiki Kaisha CELLULAR IMMUNOGENICITY POTENTIATING COMPOSITION CONTAINING $g(a)-GLYCOSYLCERAMIDE
WO2003009812A2 (en) * 2001-07-25 2003-02-06 New York University Use of glycosylceramides as adjuvants for vaccines against infections and cancer
EP1371375A1 (en) * 2001-02-21 2003-12-17 Consejo Superior De Investigaciones Cientificas Vaccine to protect animals against leishmania
WO2003105769A2 (en) * 2002-06-13 2003-12-24 New York University Synthetic c-glycolipid and its use for treating cancer infectious diseases and autoimmune diseases
WO2004028475A2 (en) * 2002-09-27 2004-04-08 Biomira, Inc. Glycosylceramide analogues
WO2005039633A1 (en) * 2003-10-24 2005-05-06 Mologen Ag Agent for treating leishmania infections

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0703295A1 (en) * 1994-09-26 1996-03-27 Institut Pasteur Vaccine composition comprising recombinant BCG expressing gp 63 fusion protein
EP1018548A1 (en) * 1997-09-22 2000-07-12 Kirin Beer Kabushiki Kaisha CELLULAR IMMUNOGENICITY POTENTIATING COMPOSITION CONTAINING $g(a)-GLYCOSYLCERAMIDE
WO2000039298A1 (en) * 1998-12-23 2000-07-06 C.B.F. Leti S.A. Chimeric gene encoding the antigenic determinants of four proteins of l. infantum
EP1371375A1 (en) * 2001-02-21 2003-12-17 Consejo Superior De Investigaciones Cientificas Vaccine to protect animals against leishmania
WO2003009812A2 (en) * 2001-07-25 2003-02-06 New York University Use of glycosylceramides as adjuvants for vaccines against infections and cancer
WO2003105769A2 (en) * 2002-06-13 2003-12-24 New York University Synthetic c-glycolipid and its use for treating cancer infectious diseases and autoimmune diseases
WO2004028475A2 (en) * 2002-09-27 2004-04-08 Biomira, Inc. Glycosylceramide analogues
WO2005039633A1 (en) * 2003-10-24 2005-05-06 Mologen Ag Agent for treating leishmania infections

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
AHMED S B H ET AL: "A comparative evaluation of different DNA vaccine candidates against experimental murine leishmaniasis due to L. major", VACCINE, BUTTERWORTH SCIENTIFIC. GUILDFORD, GB, vol. 22, no. 13-14, 16 April 2004 (2004-04-16), pages 1631 - 1639, XP004500416, ISSN: 0264-410X *
COUTINHO SERGIO G ET AL: "T-cell responsiveness of American cutaneous leishmaniasis patients to purified Leishmania pifanoi amastigote antigens and Leishmania braziliensis promastigote antigens: Immunological patterns associated with cure", EXPERIMENTAL PARASITOLOGY, vol. 84, no. 2, 1996, pages 144 - 155, XP002394033, ISSN: 0014-4894 *
DUMONTEIL ERIC ET AL: "DNA vaccines induce partial protection against Leishmania mexicana.", VACCINE, vol. 21, no. 17-18, 16 May 2003 (2003-05-16), pages 2161 - 2168, XP002394031, ISSN: 0264-410X *
SOONG LYNN ET AL: "Leishmania pifanoi amastigote antigens protect mice against cutaneous leishmaniasis", INFECTION AND IMMUNITY, vol. 63, no. 9, 1995, pages 3559 - 3566, XP002394032, ISSN: 0019-9567 *

Also Published As

Publication number Publication date
WO2006058243A2 (en) 2006-06-01

Similar Documents

Publication Publication Date Title
IL258718A (en) Human anti-il-23 antibodies,compositions, methods and uses
WO2005002621A3 (en) Methods to elicit, enhance and sustain immune responses against mhc class i-restricted epitopes, for prophylactic or therapeutic purposes
WO2005037190A3 (en) Multiplex vaccines
ZA200706251B (en) Immune response modifier formulations and methods
WO2003084467A3 (en) Epitope constructs comprising antigen presenting cell targeting mechanisms
WO2005079506A3 (en) Systemic immune activation method using nucleic acid-lipid complexes
WO2009133378A3 (en) Products and methods for stimulating an immune response
WO2006039470A9 (en) Anti- amyloid antibodies, compositions, methods and uses
IL180762A0 (en) Insulin-oligomer conjugates, formulations and uses thereof
WO2007060117A3 (en) Chimeric keratin-binding effector proteins
ZA200705132B (en) Methods for increasing the immune response in an animal
WO2006081007A3 (en) Use of flagellin in tumor immunotherapy
AP2005003234A0 (en) Lectin compositions and methods for modulating an immune response to an antigen.
WO2006055024A3 (en) Minicells as vaccines
WO2006071989A3 (en) Methods to elicit, enhance and sustain immune responses against mhc class i-restricted epitopes, for prophylactic or therapeutic purposes
AU2003302165A8 (en) Prostate specific antigens, conjugates thereof, methods for their preparation and uses thereof.
WO2008064181A3 (en) Prime boost canine leishmania vaccine
WO2006054096A3 (en) Soluble bifunctional proteins
WO2005120564A3 (en) Vaccine compositions and methods
WO2003087126A3 (en) Heteroclitic analogs and related methods
WO2007078879A3 (en) Lipopeptide compositions and methods of use thereof
WO2006058243A3 (en) Leishmania antigens and related compositions and uses
WO2007002149A3 (en) Methods and compositions relating to a vaccine against prostate cancer
WO2002032455A3 (en) Vaccine
WO2006122050A3 (en) Methods and compositions for detecting immune responses

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KN KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 05852214

Country of ref document: EP

Kind code of ref document: A2